Medexus Pharmaceuticals Inc.
MEDXF
$3.64
-$0.02-0.57%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 15.95% | -2.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.95% | -2.65% | |||
| Cost of Revenue | 14.90% | -4.18% | |||
| Gross Profit | 16.56% | -1.75% | |||
| SG&A Expenses | 22.67% | -5.59% | |||
| Depreciation & Amortization | -1.75% | 1.32% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.12% | -2.77% | |||
| Operating Income | 27.58% | -1.07% | |||
| Income Before Tax | 116.66% | -774.44% | |||
| Income Tax Expenses | 87.09% | -190.98% | |||
| Earnings from Continuing Operations | 120.34% | -3,443.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 120.34% | -3,443.75% | |||
| EBIT | 27.58% | -1.07% | |||
| EBITDA | 14.99% | -3.95% | |||
| EPS Basic | 120.65% | -3,412.00% | |||
| Normalized Basic EPS | 492.00% | -129.07% | |||
| EPS Diluted | 120.65% | -3,412.00% | |||
| Normalized Diluted EPS | 492.00% | -129.07% | |||
| Average Basic Shares Outstanding | -1.43% | -0.42% | |||
| Average Diluted Shares Outstanding | -1.43% | -0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||